Stock Updates

Is this Large Market Cap Stock target price reasonable for Ionis Pharmaceuticals, Inc. (NASDAQ:IONS)?

The company in question is, Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) currently with a stock price of 29.13 (-3.22% today). The market cap for Ionis Pharmaceuticals, Inc. is 3639.69, and is in the sector Healthcare, and Drug Manufacturers РOther industry. The target price for Ionis Pharmaceuticals, Inc. is 40.73. Currently Ionis Pharmaceuticals, Inc. is trading with a P/E of *TBA, and a forward P/E of *TBA. Average volume for Ionis Pharmaceuticals, Inc. is 2321.56 and so far today it is 1189232.

Performance in the last year for Ionis Pharmaceuticals, Inc. has been *TBA. For EPS growth, Ionis Pharmaceuticals, Inc. has seen a growth of -122.60%, and is looking to grow in the next year to 11.70%. More long term stats show that EPS growth has been -3.60% over the last five years and could be 41.00% for the next five years. Ionis Pharmaceuticals, Inc. has seen sales growth quarter over quarter at -68.00%, with EPS growth quarter over quarter at -263.90%. The 20-day simple moving average is -12.27%, with the 200-day simple moving average coming to -14.23%.

Since the IPO date for Ionis Pharmaceuticals, Inc. on the 5/17/1991, Ionis Pharmaceuticals, Inc. has seen performance year to date to be -40.03%. With Ionis Pharmaceuticals, Inc. trading at 29.13, the dividend yield is *TBA, and the EPS is -1.89.

So could Ionis Pharmaceuticals, Inc., be undervalued? Well as said before P/E is *TBA. The PEG is *TBA, P/S is 20.68 and the P/B is at 32.72. The P/cash is 5.41, with P/free cash flow at *TBA.

Ionis Pharmaceuticals, Inc. ability to deal with debt shows that the current ratio is 6.3, and the quick ratio is 6.2. This is with long term debt/equity at 4.28, and total debt/equity at 4.36.

In terms of margins, Ionis Pharmaceuticals, Inc. has a gross margin of -68.40%, an operating margin of *TBA and a profit margin of *TBA.Payout ratio for Ionis Pharmaceuticals, Inc. is *TBA. Return on assets come to -25.10% with return on investment coming to -11.30%.

Insider ownership for Ionis Pharmaceuticals, Inc., is at 0.20% and institutional ownership comes to 91.60%. Outstanding shares are at 120.92. While shares float is 119.99. The float short is currently 10.56%, and short ratio is 5.46.

Disclaimer: Remember there is a risk to your investment, this is not a recommendation, nor personal advice, never invest more than you are able too loose.

About the author

Stephen Butters

Leave a Comment